X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4276) 4276
Publication (250) 250
Newsletter (176) 176
Book Chapter (56) 56
Book Review (36) 36
Newspaper Article (30) 30
Magazine Article (21) 21
Trade Publication Article (4) 4
Conference Proceeding (3) 3
Reference (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3404) 3404
hyperkalemia (2175) 2175
male (1738) 1738
female (1509) 1509
index medicus (1183) 1183
middle aged (1016) 1016
aged (897) 897
hyperkalemia - chemically induced (892) 892
hyperkalemia - etiology (864) 864
adult (802) 802
potassium - blood (725) 725
potassium (632) 632
hyperkalemia - drug therapy (597) 597
hyperkalemia - therapy (552) 552
urology & nephrology (488) 488
hyperkalemia - complications (458) 458
risk factors (439) 439
medicine, general & internal (433) 433
electrocardiography (401) 401
hyperkalemia - diagnosis (371) 371
hyperkalemia - blood (362) 362
treatment outcome (340) 340
mortality (338) 338
animals (334) 334
care and treatment (326) 326
renal dialysis (313) 313
cardiac & cardiovascular systems (300) 300
hypertension (297) 297
spironolactone (294) 294
research (293) 293
heart failure (284) 284
retrospective studies (273) 273
aldosterone (270) 270
aged, 80 and over (265) 265
potassium - metabolism (263) 263
heart failure - drug therapy (259) 259
hyperkalemia - physiopathology (254) 254
therapy (243) 243
pediatrics (231) 231
pharmacology & pharmacy (216) 216
drug therapy (211) 211
hypokalemia (206) 206
hemodialysis (204) 204
adolescent (203) 203
kidney failure, chronic - complications (203) 203
angiotensin-converting enzyme inhibitors - adverse effects (201) 201
hypertension - drug therapy (200) 200
child (198) 198
kidney failure, chronic - therapy (198) 198
angiotensin-converting enzyme inhibitors - therapeutic use (195) 195
time factors (195) 195
infant, newborn (192) 192
drug therapy, combination (188) 188
medicine & public health (186) 186
mineralocorticoid receptor antagonists - therapeutic use (185) 185
spironolactone - adverse effects (181) 181
abridged index medicus (180) 180
kidney diseases (178) 178
spironolactone - therapeutic use (177) 177
infant (174) 174
patients (173) 173
management (172) 172
hyperkalemia - epidemiology (164) 164
heart-failure (161) 161
nephrology (159) 159
risk (159) 159
mineralocorticoid receptor antagonists - adverse effects (157) 157
diagnosis, differential (156) 156
complications and side effects (154) 154
sodium (154) 154
insulin (152) 152
chronic kidney disease (150) 150
chronic kidney failure (149) 149
diuretics - therapeutic use (148) 148
serum potassium (148) 148
emergency medicine (147) 147
medical research (146) 146
health aspects (145) 145
diabetes (144) 144
analysis (143) 143
blood pressure (140) 140
chronic kidney-disease (138) 138
hyperkalaemia (138) 138
hyperkalemia - prevention & control (135) 135
prospective studies (135) 135
anesthesiology (132) 132
angiotensin (131) 131
renin-angiotensin system - drug effects (131) 131
hyperkalemia - metabolism (130) 130
creatinine - blood (129) 129
hyponatremia (128) 128
acute kidney injury - therapy (127) 127
medicine, experimental (127) 127
diagnosis (125) 125
surgery (125) 125
glomerular filtration rate (122) 122
diuretics - adverse effects (119) 119
electrolytes (119) 119
follow-up studies (119) 119
water-electrolyte balance (119) 119
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4028) 4028
German (166) 166
French (108) 108
Japanese (74) 74
Spanish (45) 45
Italian (28) 28
Russian (23) 23
Polish (21) 21
Hungarian (10) 10
Dutch (8) 8
Korean (8) 8
Chinese (6) 6
Danish (6) 6
Norwegian (6) 6
Portuguese (5) 5
Finnish (4) 4
Serbian (4) 4
Turkish (3) 3
Croatian (2) 2
Romanian (2) 2
Bulgarian (1) 1
Czech (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 2, pp. 175 - 176
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 2, pp. 122 - 133
Journal Article
Journal Article
Circulation-Heart failure, ISSN 1941-3289, 01/2014, Volume 7, Issue 1, pp. 51 - 58
Journal Article
Diabetic Medicine, ISSN 0742-3071, 07/2017, Volume 34, Issue 7, pp. 1005 - 1008
Journal Article
Diabetologia, ISSN 0012-186X, 12/2011, Volume 54, Issue 12, pp. 2978 - 2986
The renal and cardiovascular protective effects of angiotensin receptor blocker (ARB) remain controversial in type 2 diabetic patients treated with a... 
Type 2 diabetes | Medicine & Public Health | Human Physiology | Metabolic Diseases | Internal Medicine | Diabetic nephropathy | Macroproteinuria | Angiotensin receptor blocker | CONTROLLED-TRIAL | METAANALYSIS | HEART-FAILURE | RISK | CONVERTING-ENZYME-INHIBITORS | MICROALBUMINURIA REDUCTION | TELMISARTAN | DISEASE | ENDOCRINOLOGY & METABOLISM | CANDESARTAN | HYPERTENSION | Kidney Failure, Chronic - mortality | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Diabetic Nephropathies - drug therapy | Hypertension - drug therapy | Male | Drug Therapy, Combination - adverse effects | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Imidazoles - therapeutic use | Kidney Failure, Chronic - drug therapy | Treatment Outcome | Antihypertensive Agents - therapeutic use | Diabetic Nephropathies - mortality | Proteinuria - drug therapy | Diabetes Mellitus, Type 2 - mortality | Creatinine - blood | Hyperkalemia - chemically induced | Drug Therapy, Combination - statistics & numerical data | Tetrazoles - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Asian Continental Ancestry Group - statistics & numerical data | Caregivers | Medical colleges | Diabetics | Enzyme inhibitors | Analysis | Angiotensin converting enzyme | Angiotensin | Diabetic nephropathies | Heart attack
Journal Article
Current Opinion in Nephrology and Hypertension, ISSN 1062-4821, 05/2019, Volume 28, Issue 3, pp. 238 - 244
PURPOSE OF REVIEWAlthough renin–angiotensin aldosterone system (RAAS) inhibitors have become the mainstay treatment for patients with chronic diseases,... 
heart failure | chronic kidney disease | MANAGEMENT | renin-angiotensin aldosterone system blockade | hyperkalemia | HEART-FAILURE | SERUM POTASSIUM | patiromer | SODIUM ZIRCONIUM CYCLOSILICATE | ZS-9 | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | PERIPHERAL VASCULAR DISEASE | CHRONIC KIDNEY-DISEASE | Hyperkalemia | Care and treatment | Research
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 16, pp. 1577 - 1578
The authors of this letter report that in patients with severe hyperkalemia at baseline, treatment with a single dose of sodium zirconium cyclosilicate was... 
MEDICINE, GENERAL & INTERNAL | Potassium - blood | Silicates - therapeutic use | Hyperkalemia - drug therapy | Humans | Kaplan-Meier Estimate | Sodium | Potassium | Hyperkalemia
Journal Article
Medical Clinics of North America, ISSN 0025-7125, 07/2013, Volume 97, Issue 4, pp. 667 - 679
Antibiotics have greatly changed the practice of medicine for the better. Many infections commonly treated in the outpatient setting with antibiotics (eg,... 
Drug-induced lupus | Side effects | Antibiotics | Drug interactions | DRUG-INTERACTIONS | PREVENTION | RISK | PROBIOTICS | VULVO-VAGINAL CANDIDIASIS | MEDICINE, GENERAL & INTERNAL | WARFARIN | SULFAMETHOXAZOLE-INDUCED HYPERKALEMIA | FLUOROQUINOLONES | INHIBITORS | Humans | Anti-Bacterial Agents - adverse effects | Drug Interactions
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 2015, Volume 10, Issue 1, pp. 21 - 28
Journal Article
Circulation: Cardiovascular Quality and Outcomes, ISSN 1941-7713, 01/2017, Volume 10, Issue 1
Background Heart failure guidelines recommend routine monitoring of serum potassium, and renal function in patients treated with a mineralocorticoid receptor... 
Heart failure | Medication adherence | Aldosterone antagonist | renal insufficiency | Mineralocorticoid receptor antagonist | SURVIVAL | heart failure | MILD PATIENTS HOSPITALIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | HYPERKALEMIA | GUIDELINES | medication adherence | mineralocorticoid receptor antagonist | SPIRONOLACTONE | aldosterone antagonist | ALDOSTERONE BLOCKER | EMPHASIS-HF | EPLERENONE | WORSENING RENAL-FUNCTION | Hyperkalemia - blood | United States | Humans | Heart Failure - physiopathology | Male | Practice Patterns, Physicians | Heart Failure - blood | Hyperkalemia - diagnosis | Renal Insufficiency - physiopathology | Time Factors | Aged, 80 and over | Female | Renal Insufficiency - complications | Retrospective Studies | Acute Kidney Injury - etiology | Kidney - physiopathology | Databases, Factual | Heart Failure - complications | Kidney - drug effects | Medicare | Risk Assessment | Risk Factors | Mineralocorticoid Receptor Antagonists - adverse effects | Treatment Outcome | Hospitalization | Biomarkers - blood | Acute Kidney Injury - physiopathology | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Guideline Adherence | Hyperkalemia - chemically induced | Potassium - blood | Administrative Claims, Healthcare | Aged | Drug Monitoring | Practice Guidelines as Topic | mineralocorticoids | aldosterone
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 24, pp. 2267 - 2276
This trial tested single versus dual inhibition of the renin–angiotensin–aldosterone system in ADPKD. ACE-inhibitor monotherapy controlled blood pressure in... 
RECEPTOR BLOCKER | MEDICINE, GENERAL & INTERNAL | RENIN | RAMIPRIL | COMBINATION THERAPY | ACE-INHIBITOR | BLOOD-PRESSURE CONTROL | PROTEINURIA | PROGRESSION | ALDOSTERONE SYSTEM | CONVERTING-ENZYME | Benzoates - therapeutic use | Renal Insufficiency, Chronic - etiology | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Hypertension - drug therapy | Male | Aldosterone - urine | Hypertension - etiology | Renal Insufficiency, Chronic - drug therapy | Young Adult | Glomerular Filtration Rate - drug effects | Lisinopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Adult | Female | Blood Pressure - drug effects | Drug Therapy, Combination | Polycystic Kidney, Autosomal Dominant - drug therapy | Benzimidazoles - therapeutic use | Albuminuria - etiology | Double-Blind Method | Disease Progression | Kidney Failure, Chronic - prevention & control | Adolescent | Polycystic Kidney, Autosomal Dominant - physiopathology | Polycystic Kidney, Autosomal Dominant - complications | Treatment outcome | Care and treatment | Lisinopril | Analysis | Dosage and administration | Polycystic kidney disease | Telmisartan | Hypertension | End-stage renal disease | Excretion | Inhibitor drugs | Kidneys | Polycystic kidney | Diabetes mellitus | Albumin | Aldosterone | Glomerular filtration rate | Quality of life | Hyperkalemia | Renin | Pain | Angiotensin | Blood pressure | Kidney diseases | Drug therapy | Angiotensin II
Journal Article